Get the StoQuant digest — free

Free StoQuant digest by email. No account needed. See today's research picks.

Subscribe free

BCYC vs IRD — Stock Comparison

Compare BCYC and IRD side-by-side on StoQuant: BCYC Q-Score 16 vs IRD 46; analyst signal 73 vs 77. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.

Side-by-side snapshot

• BCYC — Bicycle Therapeutics plc · Health Care · market cap $248M · Q-Score verdict Strong Sell (16.0, grade F) · analyst signal 73/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: competitive moat 100/100, analyst consensus 70/100 · weakest signals: technicals 5/100. Full BCYC research.
• IRD — Opus Genetics, Inc. · Health Care · market cap $289M · Q-Score verdict Hold (46.0, grade C) · analyst signal 77/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: AI Alpha (gem) 100/100, analyst consensus 78/100 · weakest signals: technicals 35/100, competitive moat 2/100. Full IRD research.

What you can compare

• Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
• Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
• Insider activity: Cluster scores and recent Form 4 buying.
• Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
• Strategic edges: Competitive moat and durable advantage analysis.
• Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
• Macro context: Market regime and sector rotation alignment.

Deep dive: BCYC research · IRD research. Sign in to StoQuant to run live comparisons for any tickers. Sign up free →